HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedrine Alkaloid Sensitivity Study Urged By Researchers Boozer, Daly

This article was originally published in The Tan Sheet

Executive Summary

A large, case-control study may be necessary to determine whether some people have unusually high sensitivity to the potential adverse effects of ephedrine alkaloids, researchers say in the May issue of the International Journal of Obesity

You may also be interested in...



Ephedra Rule Cites Lack Of Safety Data In Vulnerable Subjects

Research weighed by FDA in evaluating the safety of ephedrine alkaloid-containing dietary supplements was lacking in subjects that were adequately representative of the broader population, the agency maintains in the 1final rule banning the botanical

Ephedra Label Warning With Limited PDP Statement Recommended By CRN

The Council for Responsible Nutrition suggests FDA require a label warning format for ephedrine alkaloid-containing products featuring a limited principal display panel declaration that refers consumers to more information on another part of the label

Ephedrine/Caffeine Combos Safer Than Ephedrine Alone - Researcher

Combining ephedrine alkaloids with caffeine may actually diminish the potential adverse effects of taking ephedrine alone, suggested Arne Astrup, MD/PhD, University of Copenhagen, Denmark, at a Public Health Service meeting on the safety of ephedra supplements.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS130647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel